FOLLICULAR LYMPHOMA ( FL)

This early-phase study tests a new type of immune cell therapy (bispecific AbTCR-T cells) in 3 adults with relapsed or refractory B-cell lymphoma. The cells are designed to recognize two targets (CD19 and CD22) on cancer cells. The main goal is to check safety and side effects, w…

This study tests a new combination of three drugs (sonrotoclax, zanubrutinib, and rituximab) as a first treatment for people with follicular lymphoma, a slow-growing blood cancer that is not currently curable. The goal is to see if this chemotherapy-free approach can make the can…

This study looks at whether using a connected blood pressure monitor at home can help catch and manage high blood pressure early in people with certain blood cancers (like CLL or lymphoma) who are starting a type of targeted therapy called BTK inhibitors. About 40 adults will use…

This study tests whether a new drug called SCTB35, when combined with lenalidomide, works better than the standard combination of rituximab and lenalidomide for people with follicular lymphoma that has returned or stopped responding to prior therapy. About 93 adults aged 18-80 wi…

This study aims to bring a personalized cell therapy called CAR-T to Colombia for people with certain blood cancers that have come back or not responded to treatment. The therapy involves modifying a patient's own immune cells to attack cancer. The trial will check if it is safe …

This study tests a new treatment called TC011, which uses a patient's own immune cells modified to attack lymphoma cells. It is for adults with follicular lymphoma that has returned or not responded to at least two prior therapies. The main goal is to see how many patients' tumor…

This study follows 18 people who already received GF-CART01, a CAR T-cell therapy for certain blood cancers like lymphoma. Researchers will monitor participants for up to 15 years to see how long the modified cells stay in the body and whether any serious side effects appear. No …